Aruna Mani

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

Leisha A. Emens, Francisco J. Esteva, Mark Beresford et al. · The Lancet Oncology · 2020 · 375 citations

Medicine, Oncology, Pharmacology +17

Interleukin-21 Enhances NK Cell Activation in Response to Antibody-Coated Targets

Julie M. Roda, Robin Parihar, Amy Lehman et al. · The Journal of Immunology · 2006 · 118 citations · Full text

Life Sciences, Immunology, Oncology +15

IL-12 Enhances the Antitumor Actions of Trastuzumab via NK Cell IFN-γ Production

Alena Cristina Jaime‐Ramirez, Bethany L. Mundy-Bosse, SriVidya Kondadasula et al. · The Journal of Immunology · 2011 · 98 citations · Full text

Life Sciences, Immunology, Oncology +17

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

Nicholas C. Turner, Rebecca Dent, Joyce O’Shaughnessy et al. · Breast Cancer Research and Treatment · 2021 · 88 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors

Pravin T. P. Kaumaya, Kevin Foy, Joan T. Garrett et al. · Journal of Clinical Oncology · 2009 · 84 citations · Full text

Pharmacy, Immunology, Oncology +17